3D bioprinting vasculatures is perhaps the holy grail of the next industrial revolution in healthcare. Biofabrication and bioprinting of any viable three-dimensional tissue will not be successful unless the vascularization challenge has been solved. Many organizations and talents around the world are actively tackling this challenge, but where are we exactly?
Andrew received his B.Sc. in Materials Science and Engineering (2014) and M.Sc. in Biomedical Engineering (2015) from Carnegie Mellon University. He is currently a Ph.D. student in Adam Feinberg’s Regenerative Biomaterials and Therapeutics Group. The goal of Andrew’s research is to vastly improve the resolution and vascularization in 3D bioprinting to create the next generation of tissue engineered therapies such as cardiac muscle. Andrew is also a Co-Founder of FluidForm, a CMU startup that seeks to spread the FRESH 3D bioprinting technology developed in the Feinberg lab.
Jordan Miller is an Associate Professor of Bioengineering. at Rice University and Co-Founder of Volumetric, a Houston-based startup focused on next-generation biomaterials and biofabrication technologies. Miller received his bachelor’s degree in Biology from MIT in 2003 and earned his Ph.D. in Bioengineering from Rice University in 2008. His primary interests combine synthetic chemistry, 3D printing, microfabrication, and molecular imaging to direct cultured human cells to form more complex organizations of living vessels and tissues for research in regenerative medicine. Precisely engineered in vitro systems at the molecular, micro- and meso-scale are well suited to decouple the relationship between tissue architecture and cell function. These systems are now permitting comprehensive closed-loop design and optimization of large-scale engineered tissues through refinement with computer models of mass transport and assessment of their therapeutic potential in vivo.
Dr. Prafulla Chandra is an accomplished life science professional with current specialization in regenerative medicine, 3D bioprinting, and cell biology. He has a Ph.D. in Biotechnology from the University of Pune (India), and more than 16 years of combined scientific research experience. His unique combination of skills and experience include research, technology development and intellectual property related to biomedical and regenerative medicine products. Dr. Chandra has been working at the Wake Forest Institute for Regenerative Medicine (WFIRM) since the past 7 years under the mentorship of Dr. Anthony Atala, where his work in 3D bioprinting includes using extrusion and ink-jet based bioprinters for creating live tissues such as cartilage, bone, skin, urethra and many types of polymer scaffolds for tissue regeneration and diagnostic applications such dermal scaffolds, microfluidics-based cell culture and organ-on-a-chip systems. Additionally, adapting synthetic polymers for 3D bioprinting, creating self-expanding polymers, bioink development, stem-cells based therapies and organ-on-a-chip for screening and diagnostic applications are his other projects at WFIRM. In association with the Regenerative Medicine Clinical Center (RMCC) at WFIRM, Dr. Chandra has also worked on clinical translation of regenerative medicine products, which include an oxygen-generating wound dressing and a 3D bioprinted nasal septum cartilage. He was a core team member for validating a 3D bioprinter for clinical manufacturing and also participated in the writing of regulatory documents such as pre-IND and IND for submission to the US FDA. Prior to joining WFIRM, Dr. Chandra had worked at the New Jersey Center for Biomaterials (under the mentorship of Prof. Joachim Kohn, Director, New Jersey Center for Biomaterials, Rutgers University, NJ, USA), where his work included research in the fields of cell-biomaterial interactions, human skin tissue engineering, surface modification of polymers for enhancing cellular response and using synthetic polymer-based nanospheres for enhancing topical delivery of hydrophobic drugs. One of his research here led to the award of a US Patent (Patent No. 8414871) on which he is a co-inventor.
James (Jay) Hoying, Ph.D. is Partner and Chief Scientist of Advanced Solutions Life Sciences (ASLS), a company pioneering solutions in tissue fabrication and biomanufacturing. Prior to joining ASLS, Dr. Hoying was the Chief of the Division of Cardiovascular Therapeutics at the Cardiovascular Innovation Institute (CII) and a Professor in the Department of Physiology at the University of Louisville. He has over 25 years of experience in basic and applied biological sciences research with a focus in tissue biology, tissue vascularization, and the microcirculation. In addition to his numerous published works, Dr. Hoying holds patents related to vascularizing tissues and related cell-based therapies; technologies that have been translated to companies, including start-ups and ASLS. Dr. Hoying is a Fellow of the American Heart Association.
Business Development Manager, Advanced Solutions Life Sciences
Dr. Lehanna Sanders is a cellular and molecular biologist and has done research within the field of regenerative medicine for 8 years. She received her Bachelor’s degree in Cellular, Molecular, and Development Biology from Purdue University where she completed an honors thesis project in Biomedical Engineering. She then completed her PhD at Vanderbilt University where she published work in the area of molecular repair processes following acute cardiac injury. During her time at Vanderbilt, she served on the Skills Development Committee for the NHLBI Progenitor Cell Biology Consortium, as well as a member of the Board of the Directors for the Life Science Tennessee-Academic Alliance. She now works in Business Development for Advanced Solutions Life Sciences, where she is continuing to grow the field of regenerative biology through working closely with scientists and engineers to advance innovations in 3D bioprinting and biofabrication.